TY - JOUR
T1 - Mutant α-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma
AU - Menez, Jeanne
AU - Le Maux Chansac, Béatrice
AU - Dorothée, Guillaume
AU - Vergnon, Isabelle
AU - Jalil, Abdelali
AU - Carlier, Marie France
AU - Chouaib, Salem
AU - Mami-Chouaib, Fathia
N1 - Funding Information:
We thank Dr P Coulie for helpful discussions. We also thank Dr A Bensussan for critically reading the manuscript and Pr D Bellet and JP Le Vilain for rabbit polyclonal Ab production. We also thank Drs J Bernard and P Hollender for their help with cell migration assay and Dr D Grunenwald from the thoracic surgery department of the Institut Mutualiste Montsouris, Paris, France. We also acknowledge Dr P Opolon for her help with cell visualization, D Challuau for technical assistance in in vivo experiments and P Ardouin and all the staff from the IGR Animal Facility for animal care assistance. This work was supported by grants from the Institut Gustave Roussy (IGR), Institut National de la Santé et de la Recherche Médicale (INSERM), the Association pour la Recherche sur le Cancer (ARC), The Fondation de France, Comité tumeurs solides. JM was supported by a fellowship from the IGR. BLMC and GD contributed equally to this work.
PY - 2004/4/8
Y1 - 2004/4/8
N2 - The precise role of α-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated α-actinin-4, which is recognized as a tumor antigen by autologous CD8+ cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) α-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro α-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant α-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.
AB - The precise role of α-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated α-actinin-4, which is recognized as a tumor antigen by autologous CD8+ cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) α-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro α-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant α-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.
KW - Cell migration
KW - Cytoskeleton
KW - Lung carcinoma
KW - Tumor suppressor gene
KW - α-actinin-4
UR - http://www.scopus.com/inward/record.url?scp=2342473298&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1207347
DO - 10.1038/sj.onc.1207347
M3 - Article
C2 - 15048094
AN - SCOPUS:2342473298
SN - 0950-9232
VL - 23
SP - 2630
EP - 2639
JO - Oncogene
JF - Oncogene
IS - 15
ER -